Odyssey Reports Wider Q2 Loss Of $52 Mln As OD-001 Advances In Phase 2 Studies

Odyssey Therapeutics Inc. (ODTX), a clinical-stage biopharmaceutical company, on Tuesday announced financial results for the second quarter, and recorded a higher net loss due to increased spending on external Research and Development for the company's preclinical and clinical programs.